Jupiter Endovascular announced today that its Vertex catheter received FDA 510(k) clearance for the insertion of endovascular ...

It measures volatility — not direction — and can signal when markets are likely to break out or consolidate. In a recent live ...

“VTEX’s underlying business remains on a positive trajectory. Its expanding LatAm and global presence, and new product initiatives (b2b and retail media) give us confidence that the company’s ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...

CBIZ, Inc., a leading national professional services advisor, today announced the launch of Vertical Vector AI™, an artificial intelligence product designed to help middle-market businesses unlock the ...

Vertex Pharmaceuticals (VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a ...

Vertex Pharmaceuticals Incorporated just reported a robust Q2 with earnings per share of $4.52, surpassing estimates and ...